Market Place
Sourcing Support
Denali Therapeutics Reports Q3 2024 Financials & Highlights
06 Nov 2024 //
GLOBENEWSWIRE
Sanofi flunks MS study, dealing another blow to Denali pact
11 Oct 2024 //
FIERCE BIOTECH
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug
11 Oct 2024 //
REUTERS
Denali to File for FDA Accelerated Approval of Tividenofusp Alfa for MPS II
03 Sep 2024 //
GLOBENEWSWIRE
Denali Therapeutics Publishes Data On Oligonucleotide Transport Vehicle Platform
14 Aug 2024 //
GLOBENEWSWIRE
Denali Reports New Method To Transport ASOs Across Blood-Brain Barrier
14 Aug 2024 //
FIERCE BIOTECH
Denali Reports Q2 2024 Results And Business Highlights
01 Aug 2024 //
GLOBENEWSWIRE
Biogen Exits Denali Alzheimer`s Collaboration
01 Aug 2024 //
FIERCE BIOTECH
GSK, Sanofi, Denali take part in FNIH Parkinson’s biomarker project
17 Jul 2024 //
FIERCE BIOTECH
First rare disease therapies chosen for FDA START programme
05 Jun 2024 //
PHARMAPHORUM
FDA picks Denali, Neurogene and more for rare disease program
04 Jun 2024 //
FIERCE BIOTECH
Denali`s DNL126 Selected For FDA START For MPS IIIA Acceleration
03 Jun 2024 //
GLOBENEWSWIRE
Denali Therapeutics Q1 2024 Results and Highlights
07 May 2024 //
GLOBENEWSWIRE
Denali: Enrollment Complete For DNL343 ALS Trial Regimen G
01 May 2024 //
GLOBENEWSWIRE
Denali Therapeutics Announces $500 million Private Placement Equity Financing
27 Feb 2024 //
GLOBENEWSWIRE
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Amid pivot, Denali Therapeutics sends staff packing
26 Feb 2024 //
FIERCE BIOTECH
Denali-Sanofi`s ALS drug fails to meet mid-stage trial goal
17 Feb 2024 //
REUTERS
Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
16 Feb 2024 //
PRESS RELEASE
Denali reports a PhII ALS fail as RIPK1 deal with Sanofi hits another bump
16 Feb 2024 //
ENDPTS
Denali Announces Expansion of BBB-Crossing Enzyme Replacement Therapy Programs
07 Feb 2024 //
GLOBENEWSWIRE
Denali Therapeutics Announces Presentations on Its Investigational BBB
01 Feb 2024 //
GLOBENEWSWIRE
Denali Therapeutics Announces Key Anticipated 2024 Milestones
08 Jan 2024 //
GLOBENEWSWIRE
Investors in Denali from three years ago are still down 74%
14 Dec 2023 //
SIMPLY WALL
Denali Reports Third Quarter 2023 Financial Results and Business Highlights
07 Nov 2023 //
GLOBENEWSWIRE
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310
30 Aug 2023 //
GLOBENEWSWIRE
Denali, Takeda scrap PhI Alzheimer`s drug due to safety signals
09 Aug 2023 //
ENDPTS
Denali Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
PRESS RELEASE
Denali Announces Robust Reduction in Neurofilament Light (NfL) with DNL310
20 Jun 2023 //
GLOBENEWSWIRE
Biogen trims Denali-partnered Parkinson`s program in half
06 Jun 2023 //
FIERCE BIOTECH
Why Shares of Denali Therapeutics Are Up Monday
15 May 2023 //
NASDAQ
Denali Therapeutics Reports 1Q 2023 FYR and Business Highlights
08 May 2023 //
GLOBENEWSWIRE
Biogen Exercises Option with Denali to Develop Antibody Transport Vehicle Program
12 Apr 2023 //
GLOBENEWSWIRE
Denali Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented
10 Apr 2023 //
PRESS RELEASE
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Denali Announces Data from DNL310 Phase 1/2 Study for MPS II & DNL126
22 Feb 2023 //
GLOBENEWSWIRE
Denali Therapeutics Announces Presentations on ETV Development Programs
15 Feb 2023 //
GLOBENEWSWIRE
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Trial
25 Jan 2023 //
GLOBENEWSWIRE
FDA adcomm votes in favor of antifungal; Denali gets $25M from Sanofi MS trial
25 Jan 2023 //
ENDPTS
Denali Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio
09 Jan 2023 //
GLOBENEWSWIRE
CENTOGENE and Denali Extend Observational Study on Parkinson`s Disease Genetics
09 Jan 2023 //
GLOBENEWSWIRE
Denali Therapeutics Announces DNL343 Interim Ph1b Data in ALS
05 Dec 2022 //
GLOBENEWSWIRE
Denali Therapeutics Reports 3Q FYR and Business Highlights
03 Nov 2022 //
GLOBENEWSWIRE
Denali Announces Ph 1/2 Study Single Dose Healthy Volunteer Data TAK-594/DNL593
01 Nov 2022 //
GLOBENEWSWIRE
Denali Therapeutics Announces Closing of a $316 Million Public Offering
24 Oct 2022 //
GLOBENEWSWIRE
Denali Therapeutics Announces Pricing of $275 Million Public Offering
19 Oct 2022 //
GLOBENEWSWIRE
Denali Therapeutics Announces Proposed Offering of Common Stock
18 Oct 2022 //
GLOBENEWSWIRE
Investors in Denali have made a decent return of 100% over the past three years
10 Oct 2022 //
FINANCE YAHOO
Biogen & Denali Announce Initiation of the Phase 3 LIGHTHOUSE Study
03 Oct 2022 //
PRESS RELEASE
Biogen, Denali begin late-stage testing of Parkinson’s drug
03 Oct 2022 //
BIOPHARMADIVE
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
29 Sep 2022 //
NASDAQ
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310
31 Aug 2022 //
GLOBENEWSWIRE
Denali Tx Reports Second Quarter 2022 Financial Results and Business Highlights
08 Aug 2022 //
GLOBENEWSWIRE
Biogen, Denali begin Phase IIb trial of Parkinson’s disease therapy
01 Jun 2022 //
CLINICALTRIALSARENA
Denali Tx, Biogen Initaites PIIb Study of LRRK2 Inhibitor in Parkinson`s Disease
31 May 2022 //
GLOBENEWSWIRE
PharmEnable announces multi-target collaboration with Denali Therapeutics
30 May 2022 //
PRNEWSWIRE
Denali Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Denali Announces Achievement of RIPK1 Milestone for PII Trial Initiation in ALS
02 May 2022 //
GLOBENEWSWIRE
Denali Tx Appoints Alexander Schuth as COO, CFO; and more
15 Mar 2022 //
GLOBENEWSWIRE
Denali Tx says Initiation of P 1/2 Trial of DNL593 in FTD-GRN
09 Mar 2022 //
GLOBENEWSWIRE
